SignatureFD’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-535
| Closed | -$4.88K | – | 3463 |
|
|
2025
Q2 | $4.88K | Sell |
535
-284
| -35% | -$2.09K | ﹤0.01% | 2616 |
|
|
2025
Q1 | $6.51K | Buy |
819
+109
| +15% | +$798 | ﹤0.01% | 2508 |
|
|
2024
Q4 | $3.85K | Buy |
710
+199
| +39% | +$1.22K | ﹤0.01% | 2684 |
|
|
2024
Q3 | $3.69K | Buy |
511
+65
| +15% | +$595 | ﹤0.01% | 2658 |
|
|
2024
Q2 | $4.84K | Buy |
446
+101
| +29% | +$1.29K | ﹤0.01% | 2527 |
|
|
2024
Q1 | $6.46K | Sell |
345
-191
| -36% | -$4.41K | ﹤0.01% | 2461 |
|
|
2023
Q4 | $11.6K | Buy |
536
+357
| +199% | +$7.08K | ﹤0.01% | 2196 |
|
|
2023
Q3 | $3.68K | Sell |
179
-122
| -41% | -$3.52K | ﹤0.01% | 2595 |
|
|
2023
Q2 | $14.2K | Sell |
301
-86
| -22% | -$4.28K | ﹤0.01% | 2067 |
|
|
2023
Q1 | $16.2K | Buy |
387
+66
| +21% | +$2.84K | ﹤0.01% | 1985 |
|
|
2022
Q4 | $12.2K | Sell |
321
-105
| -25% | -$4.01K | ﹤0.01% | 2051 |
|
|
2022
Q3 | $17K | Buy |
426
+95
| +29% | +$3.67K | ﹤0.01% | 1833 |
|
|
2022
Q2 | $11K | Buy |
+331
| New | +$11.1K | ﹤0.01% | 2082 |
|
|
2022
Q1 | – | Sell |
-14
| Closed | -$1K | – | 3303 |
|
|
2021
Q4 | $1K | Sell |
14
-13
| -48% | -$544 | ﹤0.01% | 2987 |
|
|
2021
Q3 | $1K | Sell |
27
-57
| -68% | -$2.61K | ﹤0.01% | 2912 |
|
|
2021
Q2 | $5K | Sell |
84
-8
| -9% | -$566 | ﹤0.01% | 2300 |
|
|
2021
Q1 | $7K | Hold |
92
| – | – | ﹤0.01% | 2025 |
|
|
2020
Q4 | $8K | Sell |
92
-184
| -67% | -$13.6K | ﹤0.01% | 1798 |
|
|
2020
Q3 | $17K | Buy |
276
+76
| +38% | +$3.85K | ﹤0.01% | 1449 |
|
|
2020
Q2 | $8K | Hold |
200
| – | – | ﹤0.01% | 1651 |
|
|
2020
Q1 | $6K | Buy |
+200
| New | +$11.6K | ﹤0.01% | 1643 |
|
Other funds holding SAGE
IA
HNB
SignatureFD's SAGE Position: Q3 2025 in Review
SignatureFD sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 535 shares — an estimated $4.88K sold.
SignatureFD first reported a position in SAGE in Q1 2020 and held it in 21 quarters. The position peaked at $17K in Q3 2022. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- SignatureFD reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- SignatureFD sold 535 Sage Therapeutics shares in Q3 2025, an estimated $4.88K.
- SignatureFD first reported a position in Sage Therapeutics in Q1 2020 and held it in 21 quarters.
- SignatureFD's Sage Therapeutics position peaked at $17K in Q3 2022.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on SignatureFD's 13F filing for Q3 2025, filed 21 Oct 2025.